Ann: PMS Drug Candidate Effective In Human Brain Cells, page-30

Interesting...... see below, copy of a PYC 2017 patent announcement

PERTH, Australia, 4th October 2017: Phylogica Limited (ASXYC) (Phylogica or the
Company), developer of a leading intracellular drug delivery platform technology, is
pleased to announce it has been granted a further US patent (US 2014/0141452 A1)
covering the identification of Phylomers with the ability to enter specific endothelial
cells in the brain.

Delivering cargoes into the brain endothelial cells is a first step towards developing
better medicines for neurological conditions of the central nervous system. Discovering
and developing medicines that target the brain is significantly impeded by the blood
brain barrier, and more specifically, by brain endothelial cells which are resistant to
foreign molecules. We have now shown that brain endothelial cells are accessible to
Phylogica’s Phylomers and that these peptides could be candidates for delivering drug
cargoes into the brain. The brain represents a large market with wide unmet need,
which is expected to increase with an ageing population.

The identification of Phylomers with the potential to cross the blood brain barrier comes
from the early work of Phylogica with then pharmaceutical partner Roche, and was a
precursor to development of the Company’s next generation Functional Penetrating
Peptide (FPP) technology platform.

Commenting on the work, Phylogica’s CEO Stephanie Unwin said, “Phylogica is
developing a matrix of Phylomer classes that penetrate diverse cell types and carry
different drug cargos. Importantly, many of the Phylomers described here showed
significant specificity for brain endothelial cells, which raises two interesting points. First,
cell specificity is important because it potentially reduces dosing requirements and
toxicity. And second, by combining a cell-specific FPP with a cargo that enables gene
editing or that binds a disease target, it may be possible to develop very effective
disease-specific therapies. In the near term, The Company will continue to assess the
properties of these patented Phylomers for further validation of cell penetration and
cargo delivery.”
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
I can't help but wonder whether Roche may still be an interested party as they had an early collaboration with PYC and it would seem quite logical that with PYC's latest announcement to formally enter into clinical trials for PMS that Roche could be somewhat motivated if they have been following PYC's progress?